Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification-Reference-Cited by-同舟云学术

Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification

Published:2018-01-29 Issue:8 Volume:24 Page:1845-1852
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Echavarria Isabel,López-Tarruella Sara,Picornell Antoni,García-Saenz Jose Ángel,Jerez Yolanda,Hoadley Katherine,Gómez Henry L.,Moreno Fernando,Monte-Millan María Del,Márquez-Rodas Iván,Alvarez Enrique,Ramos-Medina Rocío,Gayarre Javier,Massarrah Tatiana,Ocaña Inmaculada,Cebollero María,Fuentes Hugo,Barnadas Agusti,Ballesteros Ana Isabel,Bohn Uriel,Perou Charles M.,Martin Miguel

Funder

Institute of Health Carlos III

FEDER

NCI

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumour immune characterisation of primary triple-negative breast cancer using automated image quantification of immunohistochemistry-stained immune cells;Scientific Reports;2024-09-13

2. Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer.;Cancer Letters;2024-09

3. Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies;Frontiers in Oncology;2024-05-28

4. Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification;Scientific Reports;2024-05-17

5. Racial/Ethnic Disparities in Pathologic Complete Response and Overall Survival in Patients With Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy;Journal of Clinical Oncology;2024-05-10